ENZ Stock Forecast 2025-2026
Distance to ENZ Price Targets
ENZ Price Momentum
10 Quality Stocks Worth Considering Now
Researching Enzo Biochem (ENZ) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ENZ and similar high-potential opportunities.
Latest ENZ Stock Price Targets & Analyst Predictions
ENZ has shown a year-to-date change of -38.0% and a 1-year change of -65.4%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ENZ. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENZ Analyst Ratings
ENZ Price Target Range
Latest ENZ Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENZ.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 4, 2014 | Craig-Hallum | Buy | Initiates | $5.50 | |
| Jul 2, 2013 | Sidoti & Co. | Neutral | Initiates | $0.00 |
Enzo Biochem Inc. (ENZ) Competitors
The following stocks are similar to Enzo Biochem based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enzo Biochem Inc. (ENZ) Financial Data
Enzo Biochem Inc. has a market capitalization of $23.06M with a P/E ratio of -0.9x. The company generates $29.09M in trailing twelve-month revenue with a -73.3% profit margin.
Revenue growth is -14.3% quarter-over-quarter, while maintaining an operating margin of -21.8% and return on equity of -12.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Enzo Biochem Inc. (ENZ) Business Model
About Enzo Biochem Inc.
Develops innovative health care products and diagnostics.
Enzo Biochem generates revenue by providing specialized diagnostic services and technologies to clinical laboratories and research facilities. Its comprehensive portfolio includes products in molecular diagnostics, immunology, and tissue processing, which enhance diagnostic capabilities and support personalized medicine initiatives.
Founded in 1976 and headquartered in New York, Enzo Biochem has positioned itself as a significant player in the biotechnology sector, focusing on advancements in medical technology and laboratory efficiency.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
125
CEO
Ms. Kara Cannon
Country
United States
IPO Year
1980
Website
www.enzo.comEnzo Biochem Inc. (ENZ) Latest News & Analysis
Enzo Biochem (NYSE: ENZ) reported improved fiscal Q2 results for the period ending January 31, 2025, showing sequential gains in revenue, gross margin, and operating profit/loss.
Enzo Biochem's improved financial results indicate operational recovery, potentially boosting investor confidence and stock performance.
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules
2 months agoEnzo Biochem, Inc. (NYSE: ENZ) is non-compliant with NYSE regulations due to low market capitalization and stockholder's equity. It has 18 months to address capital issues and 6 months for stock price compliance.
Enzo Biochem faces potential delisting due to low market cap and stock price, signaling financial instability. This may affect stock liquidity and investor confidence.
Enzo Biochem reported a loss and revenue decline in Q1 fiscal 2025, facing challenges in the life sciences tools market across regions.
Enzo Biochem's quarterly loss and revenue decline indicate financial struggles, signaling potential risks for investors regarding future profitability and market position.
Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update
3 months agoEnzo Biochem, Inc. (NYSE: ENZ) reported its financial results for Q1 of fiscal year 2024, ending October 31, 2024. Further details may be available in the full report.
Enzo Biochem's Q1 financial results can signal the company's performance trends, impacting stock valuation and investor sentiment in the biotech sector.
Enzo Biochem reports revenue growth across most geographic regions, contributing positively to its overall topline performance.
Enzo Biochem's revenue growth across most regions signals strong market demand, potentially leading to increased profitability and positive investor sentiment.
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend
4 months agoEnzo Biochem, Inc. reported its fiscal Q4 and full-year results for 2024 and declared a $0.10 cash dividend per share.
Enzo Biochem's financial results and dividend announcement indicate potential profitability and shareholder returns, influencing stock valuation and investor sentiment.
Frequently Asked Questions About ENZ Stock
What is Enzo Biochem Inc.'s (ENZ) stock forecast for 2025?
Analyst forecasts for Enzo Biochem Inc. (ENZ) are not currently available. The stock is trading at $0.44.
Is ENZ stock a good investment in 2025?
According to current analyst ratings, ENZ has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENZ stock?
Price predictions from Wall Street analysts for ENZ are not currently available. The stock is trading at $0.44.
What is Enzo Biochem Inc.'s business model?
Enzo Biochem generates revenue by providing specialized diagnostic services and technologies to clinical laboratories and research facilities. Its comprehensive portfolio includes products in molecular diagnostics, immunology, and tissue processing, which enhance diagnostic capabilities and support personalized medicine initiatives.
What is the highest forecasted price for ENZ Enzo Biochem Inc.?
Price targets from Wall Street analysts for ENZ are not currently available. The stock is trading at $0.44.
What is the lowest forecasted price for ENZ Enzo Biochem Inc.?
Price targets from Wall Street analysts for ENZ are not currently available. The stock is trading at $0.44.
What is the overall ENZ consensus from analysts for Enzo Biochem Inc.?
The overall analyst consensus for ENZ is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are ENZ stock price projections?
Stock price projections, including those for Enzo Biochem Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
